TY - JOUR
T1 - Hospital Length of Stay in the First 100Days after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia in Remission
T2 - Comparison among Alternative Graft Sources
AU - Ballen, Karen K.
AU - Joffe, Steven
AU - Brazauskas, Ruta
AU - Wang, Zhiwei
AU - Aljurf, Mahmoud D.
AU - Akpek, Görgün
AU - Dandoy, Christopher
AU - Frangoul, Haydar A.
AU - Freytes, César O.
AU - Khera, Nandita
AU - Lazarus, Hillard M.
AU - LeMaistre, Charles F.
AU - Mehta, Paulette
AU - Parsons, Susan K.
AU - Szwajcer, David
AU - Ustun, Celalettin
AU - Wood, William A.
AU - Majhail, Navneet S.
N1 - Publisher Copyright:
© 2014 American Society for Blood and Marrow Transplantation.
PY - 2014/11/1
Y1 - 2014/11/1
N2 - Several studies have shown comparable survival outcomes with different graft sources, but the relative resource needs of hematopoietic cell transplantation (HCT) by graft source have not been well studied. We compared total hospital length of stay in the first 100days after HCT in 1577 patients with acute leukemia in remission who underwent HCT with an umbilical cord blood (UCB), matched unrelated donor (MUD), or mismatched unrelated donor (MMUD) graft between 2008 and 2011. To ensure a relatively homogenous study population, the analysis was limited to patients with acute myelogenous leukemia and acute lymphoblastic leukemia in first or second complete remission who underwent HCT in the United States. To account for early deaths, we compared the number of days alive and out of the hospital in the first 100days post-transplantation. For children who received myeloablative conditioning, the median time alive and out of the hospital in the first 100days was 50days for single UCB recipients, 54days for double UCB recipients, and 60days for MUD bone marrow (BM) recipients. In multivariate analysis, use of UCB was significantly associated with fewer days alive and out of the hospital compared with MUD BM. For adults who received myeloablative conditioning, the median time alive and out of the hospital in first 100days was 52days for single UCB recipients, 55days for double UCB recipients, 69days for MUD BM recipients, 75days for MUD peripheral blood stem cell (PBSC) recipients, 63days for MMUD BM recipients, and 67days for MMUD PBSC recipients. In multivariate analysis, UCB and MMUD BM recipients had fewer days alive and out of the hospital compared with recipients of other graft sources. For adults who received a reduced-intensity preparative regimen, the median time alive and out of the hospital during the first 100days was 65days for single UCB recipients, 63days for double UCB recipients, 79days for MUD PBSC recipients, and 79days for MMUD PBSC recipients. Similar to the other 2 groups, receipt of UCB was associated with a fewer days alive and out of the hospital. In conclusion, length of stay in the first 100days post-transplantation varies by graft source and is longer for UCB HCT recipients. These data provide insight into the resource needs of patients who undergo HCT with these various graft sources.
AB - Several studies have shown comparable survival outcomes with different graft sources, but the relative resource needs of hematopoietic cell transplantation (HCT) by graft source have not been well studied. We compared total hospital length of stay in the first 100days after HCT in 1577 patients with acute leukemia in remission who underwent HCT with an umbilical cord blood (UCB), matched unrelated donor (MUD), or mismatched unrelated donor (MMUD) graft between 2008 and 2011. To ensure a relatively homogenous study population, the analysis was limited to patients with acute myelogenous leukemia and acute lymphoblastic leukemia in first or second complete remission who underwent HCT in the United States. To account for early deaths, we compared the number of days alive and out of the hospital in the first 100days post-transplantation. For children who received myeloablative conditioning, the median time alive and out of the hospital in the first 100days was 50days for single UCB recipients, 54days for double UCB recipients, and 60days for MUD bone marrow (BM) recipients. In multivariate analysis, use of UCB was significantly associated with fewer days alive and out of the hospital compared with MUD BM. For adults who received myeloablative conditioning, the median time alive and out of the hospital in first 100days was 52days for single UCB recipients, 55days for double UCB recipients, 69days for MUD BM recipients, 75days for MUD peripheral blood stem cell (PBSC) recipients, 63days for MMUD BM recipients, and 67days for MMUD PBSC recipients. In multivariate analysis, UCB and MMUD BM recipients had fewer days alive and out of the hospital compared with recipients of other graft sources. For adults who received a reduced-intensity preparative regimen, the median time alive and out of the hospital during the first 100days was 65days for single UCB recipients, 63days for double UCB recipients, 79days for MUD PBSC recipients, and 79days for MMUD PBSC recipients. Similar to the other 2 groups, receipt of UCB was associated with a fewer days alive and out of the hospital. In conclusion, length of stay in the first 100days post-transplantation varies by graft source and is longer for UCB HCT recipients. These data provide insight into the resource needs of patients who undergo HCT with these various graft sources.
KW - Hematopoietic cell transplantation
KW - Length of stay
KW - Leukemia
KW - Resource utilization
KW - Umbilical cord blood
UR - http://www.scopus.com/inward/record.url?scp=84908043609&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84908043609&partnerID=8YFLogxK
U2 - 10.1016/j.bbmt.2014.07.021
DO - 10.1016/j.bbmt.2014.07.021
M3 - Article
C2 - 25064747
AN - SCOPUS:84908043609
SN - 1083-8791
VL - 20
SP - 1819
EP - 1827
JO - Biology of Blood and Marrow Transplantation
JF - Biology of Blood and Marrow Transplantation
IS - 11
ER -
